This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Strong Sell Stocks for April 26th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Why Is Impax Laboratories (IPXL) Down 1% Since Its Last Earnings Report?
by Zacks Equity Research
Impax Laboratories (IPXL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y
by Zacks Equity Research
Impax (IPXL) reports dismal fourth-quarter results with earnings and sales coming in lower than the year-ago period as well as the estimates.
Is a Surprise Coming for Impax Laboratories (IPXL) This Earnings Season?
by Zacks Equity Research
Impax Laboratories (IPXL) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y
by Zacks Equity Research
Impax (IPXL) reported dismal third-quarter results with earnings and sales coming in lower than the year-ago period. However, the company beat estimates on both counts.
Impax Laboratories and Amneal Pharmaceuticals Agree to Merge
by Zacks Equity Research
Impax Laboratories (IPXL) and Amneal Pharmaceuticals announced an agreement to merge to form a new publicly traded company.
Impax Generic Division Progresses Well Amid Pricing Pressure
by Zacks Equity Research
Impax Laboratories' (IPXL) generic portfolio has progressed well so far this year. Moreover, approval of the generic versions of Vytorin and Concerta is a positive.
Impax Laboratories, Inc. (IPXL) in Focus: Stock Moves 20.6% Higher
by Zacks Equity Research
Impax Laboratories, Inc. (IPXL) was a big mover last session, as the company saw its shares rise nearly 21% on the day.
Impax Laboratories (IPXL) Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
Impax Laboratories (IPXL) reported positive second-quarter results with earnings and sales both beating estimates. The company has strengthened its generic portfolio with additional approvals during the quarter.
3 Drug Stocks Poised to Surpass Estimates in Q2 Earnings
by Zacks Equity Research
The first half has been pretty strong for companies in the space.
Should You Buy Impax Laboratories (IPXL) Ahead of Earnings?
by Zacks Equity Research
Impax Laboratories, Inc. (IPXL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
With Catalyst Pharmaceuticals, Inc. (CPRX) not having any marketed product in its portfolio, its focus at the Q2 conference call will be on the progress of its pipeline candidates, Firdapse, CPP-115 and CPP-109.
What's in Store for BioDelivery (BDSI) This Earnings Season?
by Zacks Equity Research
BioDelivery Sciences International (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact second-quarter results remains to be seen.
Generic Drug Stocks Take a Hit: Here's Why
by Arpita Dutt
As generic drug pricing concerns loom large, Teva (TEVA) and other players in the generic market saw their shares tumble last week.
Mylan (MYL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Mylan N.V. (MYL) is expected to focus on the performance of EpiPen and progress with the biosimilars pipeline during its second-quarter results.
Is Zoetis (ZTS) Poised for a Beat This Earnings Season?
by Zacks Equity Research
Zoetis, Inc. (ZTS) is expected to focus on performance of companion animal business during its second-quarter results.
Can Horizon Pharma (HZNP) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Horizon Pharma (HZNP) is set to report second-quarter results next week and we expect investor focus on sales of key drugs.
Is a Surprise in the Cards for Teva (TEVA) in Q2 Earnings?
by Zacks Equity Research
While the inclusion of sales from Actavis Generics acquisition may continue to pull up Teva Pharmaceutical Industries Ltd.'s (TEVA) sales, its generic segment may see weakness.
Can Prothena (PRTA) Deliver a Beat this Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is expected to report second-quarter results next week and we expect investor focus on pipeline updates.
What's in the Cards for Aerie (AERI) This Earnings Season?
by Zacks Equity Research
Aerie Pharmaceuticals (AERI) is expected to throw light on updates on Rhopressa during its second-quarter earnings call on Aug 1.
Adamis Gets FDA Nod for Generic Version of Mylan's EpiPen
by Zacks Equity Research
Shares of Adamis Pharmaceuticals Corporation (ADMP) soared more than 50% after the FDA approved the company's Epinephrine injection, USP, (0.3 mg Pre-filled single dose syringe) which is the generic version of Mylan N.V.'s (MYL) EpiPen.
Why Is Impax (IPXL) Down 2.4% Since the Last Earnings Report?
by Zacks Equity Research
Impax (IPXL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan
by Zacks Equity Research
AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.
Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan
by Zacks Equity Research
Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period
Generic Drugmakers Tumble as Perrigo Discloses DoJ Search
by Arpita Dutt
With Perrigo (PRGO) disclosing that DoJ search warrants were executed at its corporate offices, industry-wide pricing practices are back in focus.